JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell M4Gxemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2LWW2lvcGmkaYTpc44hd2ZiaIXtZY4hU1VvMUmtNVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl|MkO2JO69VQ>? MVzTRW5ITVJ?
H4 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yNkewO{DPxE1? MmHmV2FPT0WU
KGN cell M3;vRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJGtIViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkKwOUDPxE1? MVfTRW5ITVJ?
786-0 cell NX\0eXY2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV3hN5FVUW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzJ7OEmg{txO MV;TRW5ITVJ?
769-P cell M{fYWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXLLOpkxUW6qaXLpeIlwdiCxZjDoeY1idiB5NkmtVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQDJ{MkSg{txO NGDtUI9USU6JRWK=
K5 cell MoiyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{jkcmlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkCxOlI1KM7:TR?= NVe4SYFPW0GQR1XS
MLMA cell MlXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWTxPGxpUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB|MkG3JO69VQ>? MVPTRW5ITVJ?
MLMA cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnNNng2UW6qaXLpeIlwdiCxZjDoeY1idiCPTF3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zQDdyMzFOwG0> MnLsV2FPT0WU
EW-7 cell NH;UelBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkOyOlk2KM7:TR?= M2TjPHNCVkeHUh?=
SW1088 cell MnXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3HWemlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45ODZ3MTFOwG0> NXjMcWxOW0GQR1XS
MC-IXC cell MkTrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUTETpBVUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjh5N{myJO69VQ>? MVPTRW5ITVJ?
NCI-H2052 cell M1zRPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MonwTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwOVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjB6MUW3JO69VQ>? MYLTRW5ITVJ?
IGR-1 cell MlzXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVWwRWI{UW6qaXLpeIlwdiCxZjDoeY1idiCLR2KtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTJyMkig{txO MUPTRW5ITVJ?
DSH1 cell MoDJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoO5TY5pcWKrdHnvckBw\iCqdX3hckBFW0hzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6yOFI6PiEQvF2= NV7jeVljW0GQR1XS
PA-1 cell NV2yTZBkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NELV[plKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlMxODV7zszN M4q1fXNCVkeHUh?=
SK-MEL-3 cell NUDJbXl6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWrxPG9VUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwM{GyNFch|ryP NVTBOFFoW0GQR1XS
SW900 cell NXrjWHVjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4rUdmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=> NUfjPG5VW0GQR1XS
CAKI-1 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\3UmVKdmirYnn0bY9vKG:oIHj1cYFvKEODS1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPTJ5M{ig{txO Mn[yV2FPT0WU
ES1 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF:5VVlKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI5QTdizszN MUTTRW5ITVJ?
SK-N-DZ cell NEPDU4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlYzPTl3IN88US=> MVzTRW5ITVJ?
RH-1 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVvJcohq[mm2aX;uJI9nKGi3bXHuJHJJNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[4OFY{KM7:TR?= MVzTRW5ITVJ?
ES8 cell NVrOdlVwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4HnZWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62PVcxOiEQvF2= M3HQU3NCVkeHUh?=
NEC8 cell NIjRflVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3rHUWlvcGmkaYTpc44hd2ZiaIXtZY4hVkWFODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|Y6QDJizszN NXnnVol[W0GQR1XS
LNCaP-Clone-FGC cell Mn\mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1OwUmlvcGmkaYTpc44hd2ZiaIXtZY4hVE6FYWCtR4xwdmVvRlfDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45OzV|NjFOwG0> MX7TRW5ITVJ?
HCE-4 cell NXLQUFBDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVv6fmJOUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0> MoP2V2FPT0WU
U-118-MG cell MmPYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJHUuOTF6LV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xOTB4NjFOwG0> M1L6d3NCVkeHUh?=
GI-ME-N cell M1HVTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUHJcohq[mm2aX;uJI9nKGi3bXHuJGdKNU2HLV6gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA5Pzl4IN88US=> MVHTRW5ITVJ?
LB1047-RCC cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn6wTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zNkG0N{DPxE1? NXf5TnA1W0GQR1XS
HT-1080 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVTW[GozUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zOUmyNUDPxE1? NWT4W4ZDW0GQR1XS
NB69 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLGXY1KdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM2ODR5IN88US=> M4fScnNCVkeHUh?=
NCI-H1693 cell MlexS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnXwTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2PVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR2OEm1JO69VQ>? MmLWV2FPT0WU
HSC-3 cell MkC1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHTGdppKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41QTl|MzFOwG0> MYfTRW5ITVJ?
MDA-MB-231 cell M4i4PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV\hVZROUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOjNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND61OVg6QSEQvF2= MYXTRW5ITVJ?
HOS cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVfJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwN{i2N{DPxE1? MXnTRW5ITVJ?
BT-549 cell M4npNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfCTY5pcWKrdHnvckBw\iCqdX3hckBDXC13NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5QDdizszN MkCxV2FPT0WU
NB17 cell MlKwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHrXUFdKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5QTd4IN88US=> NILhc2lUSU6JRWK=
5637 cell NI\teoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke5OlUzKM7:TR?= NGPhdmxUSU6JRWK=
OVCAR-8 cell NXfzeoJST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2OyOGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTJ2M{[g{txO MXrTRW5ITVJ?
G-402 cell NWC0VldKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoD4TY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPVMxOzVizszN NHm5fIVUSU6JRWK=
BB30-HNC cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2izemlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjB5MkG4JO69VQ>? MWrTRW5ITVJ?
HCC1806 cell NYfSNm9KT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF6ME[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA5OzN7IN88US=> MYXTRW5ITVJ?
COLO-800 cell MkDaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3rvTmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz24NFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF{NkSg{txO Mn\jV2FPT0WU
FADU cell NYD3OYN{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XneWlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|Y2PTdizszN Mk\jV2FPT0WU
NCI-H1651 cell NV\uVpBPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIrocINKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwM{m0NFkh|ryP MWjTRW5ITVJ?
AGS cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFizd2ZKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFc4OTFizszN NILXfIZUSU6JRWK=
CHP-212 cell NGnLN4ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2DLW2lvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzl2MEmg{txO MVXTRW5ITVJ?
YAPC cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPuXWFKdmirYnn0bY9vKG:oIHj1cYFvKFmDUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=> NYrafIt6W0GQR1XS
GOTO cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGdQXE9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS5OVc3KM7:TR?= MWHTRW5ITVJ?
KYSE-510 cell NUj4OnFWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4TLTGlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT21NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjVzMTFOwG0> M2K1O3NCVkeHUh?=
NCI-H2342 cell M3vCVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3XVfGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{K3PEDPxE1? Mof2V2FPT0WU
BFTC-905 cell MmXLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfETY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjJ6M{Wg{txO MVvTRW5ITVJ?
EW-16 cell M1voN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWnHOWQ6UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzJyOUOg{txO M{jWRnNCVkeHUh?=
SK-MEL-30 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE[2RppKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{S1OFMh|ryP NHnF[plUSU6JRWK=
HLE cell NIXaZoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUDJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{e0PFkh|ryP MYjTRW5ITVJ?
T98G cell M1LqU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MULJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5OlM2KM7:TR?= Mm\DV2FPT0WU
HUTU-80 cell NFjveZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2jVZmlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDR{Mkig{txO MYTTRW5ITVJ?
NOS-1 cell M2nwPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF;UbJhKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46PDd4NjFOwG0> MmTQV2FPT0WU
SW780 cell M4\Sfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4nDe2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk3QTR7IN88US=> M3XqeHNCVkeHUh?=
KYSE-180 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mlv2TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTd4NUSg{txO M2\IU3NCVkeHUh?=
MDA-MB-361 cell NUmwVlZYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEXOdIZKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0{PjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lkm4OlQ4KM7:TR?= MXLTRW5ITVJ?
SNU-C2B cell NGDaUm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIfwPG1KdmirYnn0bY9vKG:oIHj1cYFvKFOQVT3DNmIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjBzMUO4JO69VQ>? M1vvZnNCVkeHUh?=
NCI-H661 cell MnntS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3X6WGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB4OUSg{txO M4L0U3NCVkeHUh?=
OE33 cell M3W2V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnfuTY5pcWKrdHnvckBw\iCqdX3hckBQTTN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6xOFM5QSEQvF2= MVXTRW5ITVJ?
TYK-nu cell M4DkOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfKTY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIyQDZ|IN88US=> NHyxW5FUSU6JRWK=
COLO-792 cell MmHTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPTJzOTFOwG0> NUThVmRDW0GQR1XS
HEL cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M33SdWlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6yOlc3KM7:TR?= M2P5[3NCVkeHUh?=
D-566MG cell MkC1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFHIdldKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN|NEmxJO69VQ>? NVLWPFdLW0GQR1XS
U031 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH7CWVJKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQyQDF4IN88US=> M4rPNXNCVkeHUh?=
COR-L23 cell M3vtTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYrvNlVjUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi52M{O0OkDPxE1? NF\JU3dUSU6JRWK=
NCI-H2452 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2fFXmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyOFUzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi53MkK4NUDPxE1? MWXTRW5ITVJ?
BB65-RCC cell M1vqcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmPaTY5pcWKrdHnvckBw\iCqdX3hckBDSjZ3LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjR3OTFOwG0> NYrx[npNW0GQR1XS
CAL-33 cell NHjPSVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVTSdZJCUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ3Nk[1JO69VQ>? Mm\VV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development, L.L.C. November 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID